Sonion and Valencell Partner to Make Biometrics Universal in Hearables and Hearing Health Markets
Sonion, the global leader in micro acoustic and micro mechanical technologies and solutions for hearing instruments and specialty earphones, and Valencell, the leading innovator in wearable biometric sensor technology, today announced a strategic partnership that will expand the boundaries for the use of biometric sensors in the ear. In the partnership Valencell provides the industry’s most advanced biometric sensor modules for hearables and wearables, which Sonion will optimize for size, power consumption and cost for in-ear and on-ear applications. The partnership focuses on designing, developing and manufacturing biometric sensing ear modules for the medical, hearing health, consumer and professional communications markets.
The partnership leverages Valencell’s expertise and experience as a leader in wearable biometrics and Sonion’s more than 40 years of experience as a leader in the development and manufacturing of products for the hearing health market. Under the partnership, Sonion will introduce a wide range of sensor modules for different applications in the ear and Valencell will continue to further develop its innovative portfolio of advanced, accurate biometric sensor capabilities for all form factors. Sonion will also integrate its world class balanced armature speakers among other components as part of the sensor modules.
Sonion’s manufacturing expertise in miniaturized components for ear-based devices is expected to result in significant reductions to the size, cost and power consumption of photoplethysmography (PPG)-based sensors for continuous heart rate, blood pressure, and other medical monitoring and fitness/wellness related functionalities into hearables, hearing aids and other ear-level devices.
The markets for hearables and hearing health devices are both predicted to show a steady growth. The consumer hearables segment is expected to grow at 48% CAGR through 2022, according to IDC, while the hearing health market is expected to continue to demonstrate stable growth numbers and increase 22% over the same period according to OrbisResearch.com
In addition, as part of the partnership, Sonion has made a strategic investment of an undisclosed amount in Valencell, making Sonion a significant shareholder in Valencell Inc.
“I am truly excited about the partnership with Valencell,” says Jesper Ahlmann Funding Andersen, President & CEO of Sonion a/s. “We are bringing the best of two worlds together. Biometric sensing is the next big thing for many of our customers, making the ear-level devices truly multi-functional. Joining forces with the global leader in this field - Valencell - brings accuracy and the possibility to add innovative new metrics to the products we develop for our customers, including advanced medical monitoring. We look forward to together setting a new standard for what is possible.”
“This partnership with Sonion brings tremendous value to the hearables and hearing health markets, as well as to our current and future customers and partners,” said Michael Dering, CEO of Valencell. “Sonion brings world-class expertise and capabilities in hearing health component development, manufacturing, and distribution. As demonstrated by Valencell’s foundational patents in biometric hearables, since foundation we have envisioned a world where traditional ear-worn devices can be used to improve public health. Valencell and Sonion share a strong vision and operating model for making major advancements in hearing health and hearable devices. We are excited about the great things to come.”
Sonion a/s is a Novo Holding a/s owned global leader in microacoustics and micromechanics for hearing health and other ear-level devices. The company – which is headquartered in Roskilde, Denmark - employs over 5.500 employees across sites in Denmark, Holland, USA, China, Poland, Vietnam and Philippines.
Valencell produces the most accurate wearable biometric sensor systems in the world and provides this patent-protected technology to consumer electronics manufacturers, mobile device and accessory makers, medical device makers, sports and fitness brands and gaming companies for integration into their products. Protected by more than 60 granted patents and more than 100 patents pending, Valencell’s technology can be used in wearables and hearables for virtually anyone, anywhere, doing anything. Their technology is scalable to multiple form-factors such as earbuds, smartwatches, armbands and wrist devices and is currently integrated into more biometric wearable devices than any other technology provider in the world.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 17:41 | Pressemelding
Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 17:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl
Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 15:42 | Pressemelding
Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00
Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 14:00 | Pressemelding
Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu
Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 09:07 | Pressemelding
Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha
Alps Electric to Exhibit at CES 2019 as Alps Alpine for the First Time14.12.2018 07:58 | Pressemelding
Japanese comprehensive electronic components manufacturer Alps Electric Co., Ltd. (TOKYO:6770) (Ota-ku, Tokyo; President: Toshihiro Kuriyama) will exhibit at CES 2019, to open at the Las Vegas Convention and World Trade Center in Las Vegas, Nevada, in the United States on January 8. Alps Electric will be taking part as a new company, Alps Alpine Co., Ltd., for the first time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213006022/en/ Alps Alpine's new touch input device for automotive (Graphic: Business Wire) At CES 2019, an exposition of cutting-edge technologies brought together from around the world, Alps Electric will present a variety of technologies in response to the major trends in automotive development referred to as “CASE”—namely connected cars, autonomous driving, sharing and services, and electric vehicles. Making its first appearance at the show as a new company following its business integration with subs